CompletedPhase 2NCT03544567
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Athenex, Inc.
- Principal Investigator
- David Cutler, MDAthenex, Inc.
- Intervention
- Oraxol(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2018 – 2023
Study locations (10)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Texas Oncology, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Prince of Wales Hospital, Shatin, Hong Kong, Hong Kong
- National Taiwan University Hospital, Taipei, Taiwan
- Taipei Veterans General Hosptial, Taipei, Taiwan
- University College London Hospitals NHS Foundation Trust, London, United Kingdom
- The Royal Marsden NHS Foundation Trust, London, United Kingdom
- The Christie NHS Foundation Trust, Manchester, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03544567 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive